Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of alliinase, and medicinal composition

A technology of alliinase and composition, which is applied in the direction of drug combination, medical preparation containing active ingredients, pharmaceutical formula, etc., to achieve the effect of expanding the application range and reducing the amount of homocysteine

Inactive Publication Date: 2015-04-08
SHANGHAI INST OF PHARMA IND CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But at present, there is no report about the application of alliinase in the prevention and treatment of hyperhomocysteinemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of alliinase, and medicinal composition
  • Applications of alliinase, and medicinal composition
  • Applications of alliinase, and medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Decomposition of alliinase to Hcy

[0026] 1. Decomposition of Hcy by alliinase in sucrose activity assay buffer

[0027] 1. Test method

[0028] Prepare Hcy into 50, 100, 200, 300 and 400 μmol / L solutions with sucrose activity assay buffer, take 240 μl of each concentration, add 240 μl to alliinase solution prepared with sucrose activity assay buffer, and make alliin The unit of enzyme activity is 100u / ml, put it in a constant temperature water bath at 35°C for reaction immediately, take 240 μl of the above-mentioned reaction sample after 1 hour according to the sample processing method (references: Fan Xinping, Liu Dexiao, Shi Jiandang, etc., rHPLC quantitative analysis of plasma Hcy method Comparative research [J], Tianjin Medicine, 2003, 31 (9): 589-592), carry out HPLC operation (chromatographic column: C 18 Chromatographic column (3.9mm×150mm, 5μm); column temperature: 20°C; mobile phase: 0.1mol / lNaH 2 PO 4 -Na 2 HPO 4 Buffer (pH4.0, containing 3...

Embodiment 2

[0067] The therapeutic effect of embodiment 2 alliinase on rat Hhcy

[0068] 1. Test method

[0069] Test according to literature method (Ma Xuexing, Liu Wangming, Wu Baiming, etc., the influence of folic acid, vitamin B6, vitamin B12 on the high homocysteine ​​level and arteriosclerosis caused by high methionine in rabbits [J]. Hypertension Journal, 2002, 10 (1): 84-86.): 24 rats, half male and half female, weighing about 200g, were randomly divided into 4 groups: negative control group, model group, positive control group, alliinase group, 6 rats in each group , and the experiment started after one week of routine feeding. Blood was collected from the orbital venous plexus after fasting for 12 hours before modeling to determine the plasma Hcy content. After the modeling started, except the negative control group, animals in other groups were given methionine 1.5g / kg body weight once a day by intragastric administration for 6 consecutive weeks. On the 35th day of modeling,...

Embodiment 3

[0086] Example 3 The preventive effect of alliinase on hyperhomocysteinemia

[0087] 1. Experimental animals: big-eared white rabbits, grade I, male and female, body weight 2.0-2.5kg.

[0088] 2. Determination method of plasma homocysteine ​​concentration

[0089] Sample processing: Take 2-3 mL of fasting blood (anticoagulated with 0.1% EDTA), immediately cool it in an ice bath, and centrifuge within 30 minutes to collect plasma and store it at -20°C. Take 240 μL plasma as the measurement sample, add acetylcysteine ​​(final concentration 0.5mmol L -1 ) as an internal control, with 3-butylphosphine (final concentration 60mmol L -1 ) at 4°C for 30 minutes to fully reduce the sulfhydryl group, 0.6mol L -1 Treat denatured protein with perchloric acid, centrifuge at 2000g for 10min, take 50μL of supernatant and add 1.55mol·L -1 NaOH 10μL, boric acid buffer 125μL (0.125mol L -1 , pH 9.5, containing EDTA 4mmol·L -1 ), 50μL SBD-F (1g L -1 ), in a water bath at 60°C for 60 min, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses applications of alliinase in the preparation of preparations for reducing the homocysteine amount, and the preparation of medicines for preventing or treating hyperhomochysteinemia or preventing hyperhomochysteinemia-related diseases to expand the application range of the alliinase and provide a new approach for controlling the hyperhomochysteinemia and the hyperhomochysteinemia-related diseases. The invention also discloses a medicinal composition.

Description

technical field [0001] The invention relates to the application of alliinase in the field of medicine and a pharmaceutical composition. Background technique [0002] Homocysteine ​​(Hcy) is a sulfur-containing amino acid and an important intermediate product in the metabolism of methionine. Studies have shown that homocysteine ​​can damage blood vessel walls by producing superoxide and peroxide, change coagulation factors, cause platelet aggregation, and increase the tendency of thrombosis and atherosclerosis. At present, it has been recognized that hyperhomocysteinemia (Hhcy) is another independent risk factor for cardiovascular and cerebrovascular diseases (such as atherosclerotic disease, senile dementia, etc.) in addition to hyperlipidemia, smoking and other factors . In addition, studies have reported in recent years that in addition to homocysteine, it is also related to various diseases such as neural tube defects, preeclampsia, Parkinson's disease, slow fetal growt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/51A61P25/28A61P9/10A61P25/00A61P25/08A61P25/16A61P13/12A61P43/00
Inventor 刘全海来庆勤刘英刘珉宇张瑱黄晓玲肖璘吴学军孙海燕蔡立秦燕徐智儒
Owner SHANGHAI INST OF PHARMA IND CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com